Summary
Highlights
The video introduces eight stocks suitable for purchase in 2026, highlighting their strong growth potential and attractive valuations. The host emphasizes fundamental analysis over share price, noting that a stock's price doesn't solely dictate its value. The selected stocks span technology, healthcare, consumer discretionary, and communication services.
Amazon is presented as a diversified business with e-commerce, AWS (cloud services), advertising, and AI initiatives. Despite being a large company, it was a laggard among Magnificant 7 stocks in the past year due to significant investments. The video suggests 2026 will see these investments pay off, leading to increased margins and free cash flow. Its forward EV to EBITDA of 13.1 times is near historical lows, indicating an attractive valuation for long-term investors.
Merck offers defensive growth, balancing stability with expansion. Despite concerns about Keytruda's patent expiration, the company's strong free cash flow (30% margins) supports its 3.2% dividend yield, which has grown for 15 consecutive years. Its forward P/E of 10 times for future years makes it appealing for patient investors.
Nvidia is highlighted as a stock whose earnings growth has outpaced its significant share price appreciation. With massive revenue and operating profit increases (1,500% and 2,800% respectively since 2019), its forward P/E of 24.7 times and PEG ratio well below one suggest it remains cheap relative to its growth prospects. The flat stock performance since August 2025 is seen as an accumulation opportunity.
S&P Global is described as a 'quiet compounder' within the financial sector, benefiting from expected increases in M&A and IPOs in 2026. It operates in a duopoly with Moody's and boasts consistent growth, record operating profits, and a healthy 36.4% free cash flow margin. Despite a small dividend yield, it's a Dividend King, having increased payouts for over 50 years. Its current P/E and free cash flow multiples are below their 5-year averages, indicating a slight discount.
TSM is positioned as a key AI infrastructure play, manufacturing chips for major tech companies like Nvidia and AMD. While geopolitical risks with China exist, its essential role, high barriers to entry, advanced technology, and massive backlog (record revenues, operating profits, and free cash flow) make it a 'must-own' stock. Its forward P/E of 25.1 times and PEG ratio of one are attractive considering its 25% growth.
Netflix has transitioned from a growth-focused company to a cash flow generation story. Despite recent flat share performance, it's considered a high-quality business at a great valuation. The potential acquisition of Warner BrosDiscovery offers a win-win scenario: either enhancing offerings or receiving a substantial breakup fee. With free cash flow approaching $10 billion and a forward P/E of 27.9 times based on an expected 28% earnings growth, it has a favorable PEG ratio of one.
AbbVie combines share price appreciation with a reliable and growing high-yield dividend. Despite losing patent protection for Humira, its management has successfully diversified the business with new drugs and a robust pipeline. Revenues and free cash flow are growing to new highs, with strong free cash flow margins. It offers a 3.1% dividend yield, growing 7% annually, and has increased its dividend for 12 consecutive years. A forward P/E of 15.7 times and a PEG ratio of 0.7 make it an attractive healthcare stock.
Micron is presented as an AI memory leader that has seen insane growth but remains 'cheap' due to its cyclical nature. Its memory products are crucial for advanced chips, data centers, and AI infrastructure, leading to huge demand. Despite a bumpy ride, its revenues, operating profits, and margins are at or near all-time highs. Its fiscal 2026 forward P/E of 10.6 times, coupled with 300% earnings growth, represents a significant undervaluation due to market mispricing of cyclical stocks.